Patents by Inventor Andrew A. Pieper
Andrew A. Pieper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240100026Abstract: A method of promoting neuroprotection in a subject from axonal degeneration, neuronal cell death, and/or glia cell damage after injury, augmenting neuronal signaling underlying learning and memory, stimulating neuronal regeneration after injury, and/or treating a disease, disorder, and/or condition of the nervous system in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.Type: ApplicationFiled: May 11, 2023Publication date: March 28, 2024Inventors: Sanford MARKOWITZ, Joseph READY, Andrew PIEPER
-
Publication number: 20230310390Abstract: A method of treating neurodegeneration and/or neurodegenerative condition, disease, or disorder caused by and/or associated with elevated or aberrant 15-PGDH activity in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.Type: ApplicationFiled: August 9, 2021Publication date: October 5, 2023Inventors: Sanford Markowitz, Andrew Pieper, Hongyun Li, Edwin Vazquez Rosa, Min-Kyoo Shin, Yeojung Koh, Joseph Ready
-
Publication number: 20230112662Abstract: Provided herein, in one aspect, is a method of treating a disease or condition associated with insufficient levels of claudin-5, comprising providing a subject having insufficient levels of claudin-5, and administering an effective amount of a P7C3 compound to the subject.Type: ApplicationFiled: October 8, 2021Publication date: April 13, 2023Inventors: Andrew A. Pieper, Min-Kyoo Shin, Edwin Vázquez-Rosa, Kalyani Chaubey, Matasha Dhar
-
Patent number: 11478458Abstract: A method of promoting neuroprotection in a subject from axonal degeneration, neuronal cell death, and/or glia cell damage after injury, augmenting neuronal signaling underlying learning and memory, stimulating neuronal regeneration after injury, and/or treating a disease, disorder, and/or condition of the nervous system in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.Type: GrantFiled: August 18, 2020Date of Patent: October 25, 2022Assignees: CASE WESTERN RESERVE UNIVERSITY, BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE UNIVERSITY OF IOWAInventors: Sanford Markowitz, Joseph Ready, Andrew Pieper
-
Publication number: 20210100778Abstract: A method of promoting neuroprotection in a subject from axonal degeneration, neuronal cell death, and/or glia cell damage after injury, augmenting neuronal signaling underlying learning and memory, stimulating neuronal regeneration after injury, and/or treating a disease, disorder, and/or condition of the nervous system in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.Type: ApplicationFiled: August 18, 2020Publication date: April 8, 2021Inventors: Sanford MARKOWITZ, Joseph READY, Andrew PIEPER
-
Publication number: 20200316289Abstract: The disclosed apparatus, systems and methods relate to devices, systems and methods for improving thrombolysis via synergetic application of thrombolytics with physical factors, such as in acute ischemic stroke patients. Vibration in the low (0.5-120 Hz) frequency range is synergistic with tissue plasminogen activators (rtPA), significantly improving the effectiveness of thrombolysis without impairing blood brain barrier permeability. Administration of low frequency vibration combined with rtPA improve acute ischemic stroke outcomes.Type: ApplicationFiled: February 5, 2020Publication date: October 8, 2020Inventors: Enrique C. Leira, Thomas Schnell, Salam F. Rahmatalla, Andrew A. Pieper, Anil Chauhan
-
Publication number: 20190275014Abstract: A method of promoting neuroprotection in a subject from axonal degeneration, neuronal cell death, and/or glia cell damage after injury, augmenting neuronal signaling underlying learning and memory, stimulating neuronal regeneration after injury, and/or treating a disease, disorder, and/or condition of the nervous system in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.Type: ApplicationFiled: July 18, 2017Publication date: September 12, 2019Applicants: Case Western Reserve University, University of Texas Southwestern Medical Center, University of Iowa Research FoundationInventors: Sanford MARKOWITZ, Joseph READY, Andrew PIEPER
-
Publication number: 20190218203Abstract: Provided herein is compositions and methods for reducing one or both of axonal degeneration and neuronal cell death associated with a disease.Type: ApplicationFiled: February 12, 2018Publication date: July 18, 2019Applicant: University of Iowa Research FoundationInventors: Steven L. McKnight, Joseph M. Ready, Andrew A. Pieper
-
Publication number: 20190135809Abstract: Compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.Type: ApplicationFiled: November 5, 2018Publication date: May 9, 2019Inventors: Steven L. McKnight, Andrew A. Pieper, Joseph M. Ready, Enrique Fernandez
-
Patent number: 10183011Abstract: This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.Type: GrantFiled: February 23, 2017Date of Patent: January 22, 2019Assignee: Board of Regents of The University of Texas SystemInventors: Steven L. McKnight, Andrew A. Pieper, Joseph M. Ready, Jef K. De Brabander, Jeffrey M. Zigman
-
Patent number: 10172827Abstract: This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and protecting from neuron cell death.Type: GrantFiled: January 15, 2016Date of Patent: January 8, 2019Assignee: Board of Regents of The University of Texas SystemInventors: Steven L. McKnight, Joseph M. Ready, Andrew A. Pieper, Jef K. De Brabander
-
Publication number: 20180318255Abstract: This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.Type: ApplicationFiled: April 30, 2018Publication date: November 8, 2018Inventors: Steven L. McKnight, Andrew A. Pieper, Joseph M. Ready, Jef K. De Brabander
-
Publication number: 20180127367Abstract: This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.Type: ApplicationFiled: January 4, 2018Publication date: May 10, 2018Inventors: Steven L. McKnight, Andrew A. Pieper, Joseph M. Ready, Jef K. De Brabander
-
Patent number: 9962368Abstract: This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.Type: GrantFiled: August 24, 2012Date of Patent: May 8, 2018Assignee: Board of Regents of the University of Texas SystemInventors: Steven L. McKnight, Andrew A. Pieper, Joseph M. Ready, Jef K. De Brabander
-
Patent number: 9902713Abstract: Provided herein are compositions and methods for reducing one or both of axonal degeneration and neuronal cell death associated with a disease or traumatic brain injury. An aminopropyl carbazole agent with potent neuroprotective properties is described. Specifically, (?)-(S)-N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine, is proposed as a new pharmacological agent for protecting patients against axonal degeneration and chronic consequences of TBI.Type: GrantFiled: November 11, 2014Date of Patent: February 27, 2018Assignees: Board of Regents of the University of Texas System, University of Iowa Research FoundationInventors: Steven L. McKnight, Joseph M. Ready, Andrew A. Pieper
-
Patent number: 9884820Abstract: This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.Type: GrantFiled: August 29, 2016Date of Patent: February 6, 2018Assignee: Board of Regents of the University of Texas SystemInventors: Steven L. McKnight, Andrew A. Pieper, Joseph M. Ready, Jef K. De Brabander
-
Publication number: 20180002295Abstract: Provided herein is compositions and methods for treating anxiety, obsession and/or pathologically compulsive behavior associated with various neuropsychiatric diseases.Type: ApplicationFiled: January 25, 2016Publication date: January 4, 2018Inventors: Andrew A. PIEPER, Gregory FRIESTAD
-
Publication number: 20170307592Abstract: Provided herein are methods for identifying a compound having cell-protective (e.g., neuroprotective) activity. Compounds identified therefrom are also provided. These compounds can be used to treat various diseases, disorders, or conditions associated with, for example, unwanted cell death.Type: ApplicationFiled: May 8, 2017Publication date: October 26, 2017Applicant: University of Iowa Research FoundationInventors: Steven L. McKnight, Joseph M. Ready, Andrew A. Pieper, Gelin Wang, Ting Han
-
Publication number: 20170305906Abstract: Compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.Type: ApplicationFiled: July 7, 2017Publication date: October 26, 2017Inventors: Steven L. McKnight, Andrew A. Pieper, Joseph M. Ready, Enrique Fernandez
-
Patent number: 9701676Abstract: Compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.Type: GrantFiled: August 23, 2013Date of Patent: July 11, 2017Assignee: Board of Regents of the University of Texas SystemInventors: Steven L. McKnight, Andrew A. Pieper, Joseph M. Ready, Enrique Fernandez